Breaking News Instant updates and real-time market news.

NTRA

Natera

$30.55

0.56 (1.87%)

07:26
09/12/19
09/12
07:26
09/12/19
07:26

Natera reiterated a Top Pick at Canaccord

Canaccord analyst Mark Massaro met with Natera management and came away confident in his view the shares remain an undervalued cancer company trading at the multiple of an NIPT company. The analyst said its near-term pipeline is loaded and the company is expected to announce oncology deals in the near future. Massaro reiterated his Buy rating and $38 price target on Natera shares.

NTRA Natera
$30.55

0.56 (1.87%)

06/25/19
ADAM
06/25/19
NO CHANGE
Target $32
ADAM
Buy
Natera price target raised to $32 from $30 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Natera to $32 from $30 following the company's announcement of a 3,000 patient, multi-center, prospective study to evaluate its Prospera test for kidney transplanted rejection. The analyst said the company is executing well in its base NIPT business and is making strong advancements in its oncology and transplant pipeline. Massaro reiterated his Buy rating on Natera and said it remains a top pick.
08/08/19
PIPR
08/08/19
NO CHANGE
Target $32
PIPR
Overweight
Natera price target raised to $32 from $28 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Natera to $32 from $28 saying the core business tracking ahead of expectations and its pipeline is "compelling" following the "solid" Q2 results. The analyst keeps an Overweight rating on shares of Natera.
08/08/19
CHLM
08/08/19
NO CHANGE
Target $37
CHLM
Buy
Natera price target raised to $37 from $29 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target for Natera to $37 from $29 after a Q2 revenue beat and slight guidance raise. The analyst reiterates a Buy rating on the shares.
08/22/19
PIPR
08/22/19
NO CHANGE
PIPR
Overweight
Piper says Natera gets draft LCD for Signatera CRC assay ahead of schedule
Piper Jaffray analyst William Quirk reported that Palmetto issued a draft Local Coverage Determination, or LCD, for Natera's Signatera colorectal assay, noting this was ahead of schedule as management had guided for the end of 2019 or early 2020. The draft LCD is "generally favorable," as the company will get a series of payments for minimal disease monitoring and a final LCD would open a greater than $8B opportunity for Natera, according to Quirk, who keeps an Overweight rating on Natera shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.